Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyAmyloidosisTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
July 17
 · 
Reactions
A MyAmyloidosisTeam Member

I too have cardiac Amy wild type and only attempted 6 min walk once and didn't manage it. For the past 3 years check ups they don't even ask me to attempt it!

July 21
A MyAmyloidosisTeam Member

I too did the 6 min walk and completed ur but didn’t walk very far because got dizzy and extremely SOB. I have wild type ATTR dx 2023.

July 21
MyAmyloidosisTeam

The 6-minute walk test (6MWT) is a practical and meaningful tool for tracking how wild-type ATTR amyloidosis is progressing, particularly because this type primarily affects the heart.

While it isn't part of the formal staging systems (which rely on biomarkers like NT-proBNP and eGFR), the 6MWT gives doctors a real-world Show Full Answer

The 6-minute walk test (6MWT) is a practical and meaningful tool for tracking how wild-type ATTR amyloidosis is progressing, particularly because this type primarily affects the heart.

While it isn't part of the formal staging systems (which rely on biomarkers like NT-proBNP and eGFR), the 6MWT gives doctors a real-world picture of functional ability — essentially, how well the body is coping day to day.

For wild-type ATTR amyloidosis, key factors that influence outlook include:

- How well a person can perform daily activities — which the 6MWT directly measures
- Heart-related biomarkers — tracked through blood tests
- Age — older age can affect prognosis

So while the 6MWT won't assign a formal "stage," it plays an important supporting role. A decline in walk distance over time can signal that the heart is working harder, prompting a closer look or treatment adjustments.

It's worth discussing with the care team how often this test should be done and what changes in results might mean for the treatment plan.

July 17

Related Questions

View All
A MyAmyloidosisTeam Member asked a question 💭

A MyAmyloidosisTeam Subscriber asked a question 💭